Evidence map›Paper›PMID 40741277›Full record

ArticleArchives of medical science : AMS2025

Outcomes of SARS-CoV-2 infection in patients under treatment with pharmacological immunosuppression. A Swiss cohort study.

Antonio Galante, Benedetta Terziroli Beretta-Piccoli, Alberto Pagnamenta, Lorenzo Ruinelli, Massimo Leo, Andrea De Gottardi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Antonio GalanteGastroenterology and Hepatology, Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Lugano, Switzerland.
Benedetta Terziroli Beretta-PiccoliEpatocentro Ticino, Università della Svizzera Italiana, Lugano, Switzerland.
Alberto PagnamentaIntensive Care Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Lorenzo RuinelliICT (Information and Communication Technologies), Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Massimo LeoGastroenterology and Hepatology, Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Lugano, Switzerland.
Andrea De GottardiGastroenterology and Hepatology, Ente Ospedaliero Cantonale, Università della Svizzera Italiana, Lugano, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The impact of pharmacological immunosuppression (IS) on COVID-19 outcomes is unclear. This study aimed to investigate the outcomes of hospitalised patients undergoing IS and focussed on length of hospital stay, admission to intensive care unit (ICU) and mortality. Material and methods: Patients admitted to public hospitals in southern Switzerland with SARS-CoV-2 infection ( Results: Thirty-five patients (7.9%, 65.7% male, median age 70.6 years) were treated with IS at the time of hospital admission. Compared with patients without IS, immunosuppressed patients showed higher mortality ( Conclusions: Patients under IS were at a significantly higher risk of severe and prolonged COVID-19, with higher mortality and more extended hospital stay than patients without IS.

Indexed as

autoimmunitycancerchronic obstructive pulmonary diseaseCOVID-19immunosuppressionliver diseaserheumatologySARS-CoV-2solid organ transplant

Identifiers

PMID40741277
PMCPMC12305509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.